BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Monday, March 2, 2026
See today's BioWorld
Home
» Awaiting Genasense Decision, Genta Gets $16M In Stock Sale
To read the full story,
subscribe
or
sign in
.
Awaiting Genasense Decision, Genta Gets $16M In Stock Sale
Sep. 21, 2006
By
Jennifer Boggs
The pinchpenny public market is pushing more firms to take the route of Solexa Inc., which gained a pledge for $75 million in a stock equity financing from busy Azimuth Opportunity Ltd. (BioWorld Today)
BioWorld